The Swedish company aims to expedite drug discovery via in-house and collaborated pipelines. Credit: Tapati Rinchumrus/Shutterstock. Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The partnership is […]
Boehringer Ingelheim and Salipro enter drug discovery partnership Read More »
The drug is being jointly developed and commercialised through a partnership between Lundbeck and Otsuka. Credit: Longfin Media/Shutterstock. The European Commission (EC) has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic Rxulti (brexpiprazole) for schizophrenia in adolescents aged 13 years and
EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia Read More »
The company plans to refine its AI models and algorithms and widen its automated laboratory. Credit: raker/Shutterstock. Insilico Medicine has completed a Series E financing round, raising $110m to progress the development of its pipeline of drugs and AI platform.
Insilico raises $110m to develop drug pipeline and AI platform Read More »
Rocketvax focuses on developing next-generation vaccines using its molecular biology technologies. Credit: Pormezz/Shutterstock. Emergent BioSolutions has entered a strategic financial investment agreement with Swiss Rockets to support infrastructure development, research and the expansion of the latter’s biotech portfolio. Swiss Rockets
Emergent signs financial investment agreement with Swiss Rockets Read More »
The company is preparing to progress the drug into a registrational Phase III trial for subjects with mesothelioma. Credit: PowerUp/Shutterstock. Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug
Vivace closes $35m in Series D for cancer drug development Read More »
XLRS is marked by schisis, which causes impaired visual acuity. Credit: megaflopp/Shutterstock. Atsena Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, ATSN-201, to treat X-linked retinoschisis (XLRS). Utilising
Atsena’s ATSN-201 receives FDA fast track status for XLRS Read More »
The physician-led approach of the company has resulted in achievements including significant pain improvements. Credit: DimaBerlin/Shutterstock. Vori Health has secured $53m in a Series B funding round, supporting its value-based musculoskeletal care offerings in the US. New Enterprise Associates led
Vori Health secures $53m funding to support musculoskeletal care Read More »
Built upon Entos’ collaboration with Eli Lilly & Company, the project is set to support the development of nucleic acid products for the central and peripheral nervous system. Credit: angellodeco/Shutterstock. Entos Pharmaceuticals has announced an investment of C$62m ($43.05m) from
Entos announces governments’ investment for R&D facility Read More »
WuXi XDC’s chief technology officer Dr Marie Zhu (left) with AbTis CEO Dr Tae Dong Han (right). Credit: WuXi XDC Cayman Inc./PRNewswire. Contract research, development and manufacturing organisation (CRDMO) WuXi XDC Cayman has signed a memorandum of understanding with South
WuXi XDC and AbTis collaborate for antibody-drug conjugates Read More »
MSD has invested $12bn in US capital since 2018. Credit: Katherine Welles/Shutterstock. MSD has opened a $1bn facility in Durham, in the US state of North Carolina, to increase vaccine manufacturing capacity. The development is part of a broader strategy,
MSD expands vaccine production with new $1bn facility Read More »
